FDA Approval

Ascletis Pharma unveils ASC37, a next-gen, once-monthly obesity drug claiming superior potency and convenience, challenging giants like Eli Lilly.

At a major San Francisco summit, Chinese biotechs unveiled breakthrough heart and cancer drugs, signaling a strategic shift from manufacturing to global innovation.

Flashpoint Therapeutics appoints an FDA-approved drug developer as CSO, a strategic move to accelerate its groundbreaking structural nanomedicine platform.

Adial Pharmaceuticals files a key patent to protect its personalized Alcohol Use Disorder drug, AD04, until 2045, signaling a new era for addiction medicine.

A new partnership aims to bring a revolutionary, disease-modifying stem cell therapy for knee osteoarthritis to millions of patients in Greater China.

The biopharma firm projects massive sales from its current drugs and bets big on a new Alzheimer's therapy, signaling a pivotal year of growth and innovation.

After a strategic pivot reverses a year of decline, Allurion's preliminary results show new growth. All eyes are now on the FDA for its 'procedureless' gastric balloon.

Annexon is poised for a landmark year with potential first-in-class drugs for GBS and GA, promising to reset treatment standards and offer new hope.

With pivotal cancer drug data looming and a new nuclear supply chain, Bicycle Therapeutics is betting big on its novel platform. Will 2026 be its breakout year?

Biotech firm Bright Minds Biosciences closes a massive $175M deal, fueling its race to develop novel drugs for epilepsy and rare neurological conditions.

As part of a $23B US investment, Novartis will build a cutting-edge facility in Winter Park, cementing Florida’s role in advanced cancer treatment.

A new alliance aims to advance KFRX06, a unique Parkinson's therapy that goes beyond a single target to potentially offer a more comprehensive treatment.

New research reveals a stark disconnect between clinical views and patient reality in atopic dermatitis, with millions suffering severe, overlooked impacts.

With key studies now complete, Biofrontera's light-based therapy Ameluz could soon offer a new weapon against widespread actinic keratosis and stubborn acne.

NeuroSense adds world-renowned expert Prof. Steven Arnold to its board, a major vote of confidence in its multi-target Alzheimer's drug, PrimeC.

With a major cash infusion and key pipeline milestones, Xilio Therapeutics validates its tumor-activated approach to fighting cancer and extends its runway to 2027.

Positive early human safety data for its lead drug and new candidates for Rett syndrome and MASH signal a pivotal year for ProQR's Axiomer technology.

With a key FDA meeting set, Trevi Therapeutics pushes its drug Haduvio into late-stage trials, offering hope for millions with no approved treatments.

A new vectorized antibody therapy for ALS, VTx-002, has been granted FDA Fast Track status, accelerating its path to patients battling the disease.

A newly validated genetic test accurately predicts melanoma risk, offering a non-invasive alternative to the standard surgical biopsy for many patients.